Vystar Corporation filings document its status as a reporting operating company and its compliance calendar for periodic SEC reports. The available Form 12b-25 notification covers the delayed Form 10-K for the annual period ended December 31, 2025, and records the registrant name, SEC file number, CUSIP, form type, reporting period and stated late-filing basis.
Vystar Corporation reported another quarterly loss and continued financial strain for the three months ended March 31, 2026. Revenue fell to $6,147 from $12,657 a year earlier, while gross profit was essentially flat at $4,272. Operating expenses of $281,122 produced a loss from operations of $276,850 and a net loss of $364,779, or $0.01 per share.
Liquidity remains extremely tight. Cash was only $9,907 against total current liabilities of $7,338,549, resulting in a working capital deficit of about $7 million and a stockholders’ deficit of $6,900,522. Management notes an accumulated deficit of roughly $61.7 million and explicitly states there is substantial doubt about the company’s ability to continue as a going concern.
The balance sheet is burdened by related party debt, including a Blue Oar term convertible note with a 12% rate and associated derivative liabilities of $423,632, plus defaulted notes and arrears to the Rotman family. Capital remains highly structured, with three series of cumulative convertible preferred stock that could convert into 30,712,937 common shares, far exceeding the 24,621,094 common shares currently outstanding.
There are a few offsetting developments. Vystar successfully prevailed in long-running EMA Financial litigation and was awarded $497,439.58 in attorneys’ fees, and it holds federal net operating loss carryforwards of about $39.2 million. Subsequent to quarter-end, the company signed a binding letter of intent to acquire 50% of Capital R3alm, Inc. in exchange for Series B preferred shares that would give Capital R3alm a 34% ownership stake in Vystar, aiming to expand into a Web3-focused financial technology ecosystem alongside its existing RxAir air purification and Vytex latex businesses.
Vystar Corporation filed its annual report for the year ended December 31, 2025, showing a net loss attributable to Vystar of $1,531,658 as revenue fell to $54,821, down about 60% from 2024. The decline was driven by lower Vytex and RxAir sales, including reduced orders from a former major customer and the absence of a prior-year bulk Vytex sale.
The company ended 2025 with only $4,454 of cash, a working capital deficit of roughly $6.6M and an accumulated deficit of about $61.4M. Auditors highlighted substantial doubt about Vystar’s ability to continue as a going concern. Operations are being funded through related-party debt, stock subscriptions and small equity issuances, while management seeks to boost RxAir distribution and Vytex licensing.
Rotmans furniture operations remain classified as discontinued. In long-running litigation with EMA Financial, the courts upheld prior rulings in Vystar’s favor and the District Court awarded Vystar $497,439.58 in attorneys’ fees and costs, which EMA has appealed. The company also continues to invest in product and technology initiatives, including new RxAir models, expanded Vytex applications through its Corrie MacColl partnership, and Fluid Energy Conversion prototypes, despite limited financial resources.
VYSTAR CORPORATION notified the SEC it cannot timely file its Form 10-K for the period ended December 31, 2025 because it is unable to complete the 10-K and provide it to auditors for review without unreasonable effort or expense. The company states it believes it will file within the 15-calendar day extension under Rule 12b-25.
Vystar Corporation reported Q3 2025 results showing very limited sales and ongoing losses. Revenue was $20,385, led by air purification units of $14,812 (72.7% of sales). Gross profit was $15,365, offset by operating expenses of $262,341, resulting in an operating loss of $246,976 and a net loss of $271,387 (basic and diluted loss per share $0.01). For the nine months, revenue was $44,657 with a net loss of $1,236,593.
Liquidity remains strained: cash was $16,584, current liabilities totaled $6,725,826 against current assets of $390,602, and stockholders’ deficit was $(6,242,094). Management states there is substantial doubt about the company’s ability to continue as a going concern.
The balance sheet includes a related party term note (Blue Oar) with a carrying amount of approximately $750,000 and a related derivative liability of $356,142. Share-based compensation expense was $199,097 in Q3. Common shares outstanding were 22,485,017 as of November 12, 2025.